PT - JOURNAL ARTICLE AU - Agarwal, Anup AU - Mukherjee, Aparna AU - Kumar, Gunjan AU - Chatterjee, Pranab AU - Bhatnagar, Tarun AU - Malhotra, Pankaj AU - Latha, B AU - Bundas, Sunita AU - Kumar, Vivek AU - Dosi, Ravi AU - Khambholja, Janak Kumar AU - de Souza, Rosemarie AU - Mesipogu, Raja Rao AU - Srivastava, Saurabh AU - Dube, Simmi AU - Chaudhary, Kiran AU - S, Subash AU - Mattuvar K, S. Anbuselvi AU - Rajendran, V AU - Sundararajaperumal, A AU - Balamanikandan, P AU - Maheswari, R S Uma AU - Jayanthi, R AU - Ragunanthanan, S AU - Bhandari, Sudhir AU - Singh, Ajeet AU - Pal, Ashok AU - Handa, Anjali AU - Rankawat, Govind AU - Kargirwar, Ketan AU - Regi, Joyce AU - Rathod, Darshana AU - Pathrose, Edwin AU - Bhutaka, Nirankar AU - Patel, Mayur H AU - Verma, Rahul J AU - Malukani, Kamal AU - Patel, Shivani AU - Thakur, Apurv AU - Joshi, Satish AU - Kulkarni, Rashmi AU - Suthar, Nilay N AU - Shah, Nehal M AU - Purohit, Hemang M AU - Shah, Cherry K AU - Patel, Monila N AU - Shah, Saket AU - Shah, Smit H AU - Memon, Tehsim AU - Beriwala, Vishal R AU - Jashnani, Kusum AU - Ezzy, Fatema AU - Agrawal, Simran AU - Bhadade, Rakesh AU - N, Atish M AU - Madke, Tushar AU - Kavishwar, Vikash AU - Waghmare, Ramesh AU - Valvi, Nitin AU - Chander, B Thrilok AU - Sekhar, A Vinaya AU - Maurya, Akhilesh Kumar AU - Hemanth, K AU - Nagamani, K AU - Sudha, K AU - Chandra, T Ravi AU - Rao, K Tushara AU - Vyshnavi, J AU - Upadhyay, Rashmi AU - Bahadur, Shalini AU - Pathak, Rambha AU - Seth, Shikha AU - Gupta, Rakesh AU - Saxena, Rita AU - Dwivedi, Preksha AU - Malik, Reeni AU - Chourasia, Deepti AU - Lalwani, Jaya AU - Sharma, UM AU - Marko, JL AU - Suri, Amit AU - Kumar, Vijay AU - Kaushik, Rajnish AU - Kodan, Parul AU - Acharya, Bhabani Prasad AU - Gaur, Kuldeep Kumar AU - Gupta, Anubhav AU - Sachdeva, Prerna AU - Dogra, Shruti AU - Jindal, Aikaj AU - John, M Joseph AU - Dhanju, Avtar Singh AU - Khetrepal, Ranjana AU - Sharma, Neeraj AU - Kukar, Neetu AU - Kavita, Divya AU - Kumar, Rajesh AU - Mahajan, Rajesh AU - Singh, Gurpreet AU - Kaur, Jaspreet AU - Singh, Raminder Pal AU - Bassi, Rajni AU - Parikh, Swapneil AU - Shrivastav, Om AU - Shastri, Jayanthi AU - Desai, Maherra AU - Udupa, Shreevatsa AU - Bafna, Varun A AU - Barge, Vijay AU - Madane, Rajendra AU - Yadav, Sheetal AU - Mishra, Sanjeev AU - Bajpayee, Archana AU - Garg, M K AU - Bohra, G K AU - Nag, Vijaylakshmi AU - Anne, Puneeth Babu AU - Nadeem, Mohd AU - Singh, Pallavi AU - Niwas, Ram AU - Khaire, Niranjan Shiwaji AU - Sharma, Rattiram AU - Singh, Mini p AU - Sachdeva, Naresh AU - Sachdev, Suchet AU - Hans, Rekha AU - Suri, Vikas AU - Yaddanapudi, L N AU - Lakshmi, PVM AU - Singh, Neha AU - Bhushan, Divendu AU - Kumar, Neeraj AU - Tambe, Muralidhar AU - Salvi, Sonali AU - Kadgi, Nalini AU - Sangle, Shashikala AU - Nakate, Leena AU - Joshi, Samir AU - Karyakarte, Rajesh AU - Goyanka, Suraj AU - Sharma, Nimisha AU - Verma, Nikhil AU - Das, Asim AU - Bahl, Monika AU - Wadhwa, Nitya AU - Bhat, Shreepad AU - Deshmukh, Shweta AU - Wagh, Vrushali AU - Kulkarni, Atul AU - Yardi, Tanvi AU - Kalgud, Ram S AU - Reddy, Purushottam AU - Yevoor, Kavitha AU - Gajula, Prashanth AU - Maleyur, Vivek AU - S, Medini AU - HN, Mohith AU - Gurtoo, Anil AU - Sud, Ritika AU - Pahuja, Sangeeta AU - Prakash, Anupam AU - Gogoi, Parijat AU - Shukla, Shailja AU - Reddy, D Himanshu AU - Chandra, Tulika AU - Pandey, Saurabh AU - Maurya, Pradeep AU - Wahid, Ali AU - Kumar, Vivek AU - Upadhyay, Kamlesh AU - Bhatnagar, Nidhi AU - Shah, Nilima AU - Shah, Mamta AU - Patel, Tarak AU - Jaiswal, Ram Mohan AU - Jain, Ashish AU - Sharma, Shweta AU - Rijhwani, Puneet AU - Gupta, Naveen AU - Patel, Tinkal C AU - Solu, Mahesh G AU - Patel, Jitendra AU - Shah, Yash R AU - Jarag, Mayur AU - Godbole, Varsha AU - Shah, Meenakshi AU - Raj, Rikin AU - Nagori, Irfan AU - Jha, Pramod R AU - Shah, Arti D AU - Yeeli, Gowtham AU - Jain, Archit AU - Gill, Rooppreet Kaur AU - Babu, KV Sreedhar AU - Babu, B Suresh AU - Mohan, Alladi AU - Vengamma, B AU - Sekhar, K Chandra AU - Damam, Srinivasulu AU - Narsimhulu, K AU - Aparna, C AU - Baleswari, G AU - K, Ravindranath Reddy AU - Chandrasekhar, P AU - Panjwani, Sunil Jodharam AU - Akholkar, Pankaj J AU - Joshi, Kairavi Parthesh AU - Shah, Pragnesh H AU - Barvaliya, Manish AU - Baldi, Milind AU - Yadav, Ashok AU - Gupta, Manoj AU - Rawat, Nitin AU - Chawda, Dilip AU - Natarajan, M AU - Sintha, M AU - Kumar, David Pradeep AU - Rabbani, Fathhur AU - Khadke, Vrushali Khirid AU - Patki, Dattatray AU - Marathe, Sonali AU - D Souza, Clyde AU - Tadha, Vipul AU - Arora, Satyam AU - Gupta, Devendra Kumar AU - Dua, Seema AU - Chauhan, Nitu AU - Chahar, Ajeet Singh AU - Mammen, Joy John AU - Kumar, Snehil AU - Daniel, Dolly AU - Singh, Ravindraa AU - Dhat, Venkatesh AU - Agarwal, Yogesh AU - Arora, Sohini AU - Pathak, Ashish AU - Purohit, Manju AU - Sharma, Ashish AU - Sharma, Jayashree AU - Madkaikar, Manisha AU - Joshi, Kavita AU - Yadav, Reetika Malik AU - Bhagwat, Swarupa AU - Karnik, Niteen D AU - Gokhale, Yojana A AU - Naik, Leena AU - Margam, Sangita AU - Das, Santasabuj AU - Turuk, Alka AU - Kumar, V Saravana AU - Kanagasabai, K AU - Sabarinathan, R AU - Deshpande, Gururaj AU - Sharma, Sharda AU - Gunjikar, Rashmi AU - Shete, Anita AU - Phagiwala, Darpan AU - Patil, Chetan AU - Shingade, Snehal AU - Jarande, Kajal AU - Kaushal, Himanshu AU - Yadav, Pragya AU - Sapkal, Gajanan AU - Abraham, Priya TI - Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) AID - 10.1101/2020.09.03.20187252 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.03.20187252 4099 - http://medrxiv.org/content/early/2020/09/10/2020.09.03.20187252.short 4100 - http://medrxiv.org/content/early/2020/09/10/2020.09.03.20187252.full AB - Objectives: Convalescent plasma (CP) as a passive source of neutralizing antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. We investigated its effectiveness for the treatment of COVID-19. Design: Open-label, parallel-arm, phase II, multicentre, randomized controlled trial. Setting: Thirty-nine public and private hospitals across India. Participants: Hospitalized, moderately ill confirmed COVID-19 patients (PaO2/FiO2: 200-300 or respiratory rate > 24/min and SpO2 ≤ 93% on room air). Intervention: Participants were randomized to either control (best standard of care (BSC)) or intervention (CP + BSC) arm. Two doses of 200 mL CP was transfused 24 hours apart in the intervention arm. Main Outcome Measure: Composite of progression to severe disease (PaO2/FiO2<100) or all-cause mortality at 28 days post-enrolment. Results: Between 22 nd April to 14 th July 2020, 464 participants were enrolled; 235 and 229 in intervention and control arm, respectively. Composite primary outcome was achieved in 44 (18.7%) participants in the intervention arm and 41 (17.9%) in the control arm [aOR: 1.09; 95% CI: 0.67, 1.77]. Mortality was documented in 34 (14.5%) and 31 (13.5%) participants in intervention and control arm, respectively [aOR) 1.06 95% CI: 0.61 to 1.83]. Interpretation: CP was not associated with reduction in mortality or progression to severe COVID-19. This trial has high generalizability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A priori measurement of neutralizing antibody titres in donors and participants may further clarify the role of CP in management of COVID-19.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that TB is a member of the National Task Force for COVID-19 which approved the protocol. AM, AA, GK, AT, TB, VS, KK, RS, SD, GD, SS, RG, AS, DP, CP, SS, KJ, HK, PDY, GS, PA, MM, RMY are employed with ICMR, the funding source for the trial. PC was an employee of ICMR during the trial. The funding source (ICMR) has no financial interest in the investigational product. No other author has any competing financial or non-financial interest.Clinical TrialCTRI/2020/04/024775Funding StatementThis multi-centric study was funded by ICMR, an autonomous Government-funded medical research council. The National Task Force for COVID-19, a committee formed by ICMR to respond to the pandemic has reviewed and approved this study. The Central Implementation Team at ICMR was responsible for study design, study coordination, data analysis, data interpretation and writing of the report. Patient enrolment, data collection and actual conduct of the study was done at public and private hospitals independently and the investigators in ICMR had no role in it. The funding source has no financial interest in the investigational product. The corresponding author at ICMR had access to all the data, is the guarantor for the current work and holds final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics comittee at the Indian council Medical Research, India and Intitutional review boards of all participating institutes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual patient level data, collected in connection with the PLACID Trial, along with a data dictionary defining the variable fields has been developed and is available with the corresponding author. De-identified participant level data with data dictionary, or a sub-set thereof, may be made available upon written request to the corresponding author. Additional documents, including the study protocol, statistical analysis plan have been made available as supplementary files within the original submission. Results of secondary or sub-group analyses will be provided on request. Data will be made available, upon request once the trial is published. Data requests should be accompanied by a brief proposal outlining the analysis plan, which may be carried out with investigator support. A signed data access agreement may be needed to ensure data safety and compliance with national rules regarding data sharing.